UK MHRA 'Could Set Up Standalone System' But Faces Post-Brexit Loss Of Income & Influence
Executive Summary
The UK regulator is realistic about the threats Brexit poses to its income and influence, but is confident it can set up a standalone regulatory system and has some ideas for working with the European Medicines Agency under the future relationship between the UK and the EU.
You may also be interested in...
UK And EMA Could Work Together Informally After Brexit
The UK may not be able to participate in the European Medicines Agency after Brexit, but there are plenty of precedents for informal collaboration among regulatory agencies worldwide. A former European Medicines Agency executive director and legal experts talk to the Pink Sheet about what might be possible.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.